Hubei Biocause Heilen Pharmaceutical Co. Ltd. Asset Resilience Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. asset resilience ratio. Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has an Asset Resilience Ratio of 46.44% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 301211 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2019–2025)
Asset resilience ratio of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2019 to 2025. This chart shows how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s Asset Resilience Ratio has changed over time. Read debt load of Hubei Biocause Heilen Pharmaceutical Co. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 301211 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.11 Billion | 46.44% |
| Total Liquid Assets | CN¥1.11 Billion | 46.44% |
Asset Resilience Insights
- Very High Liquidity: Hubei Biocause Heilen Pharmaceutical Co. Ltd. maintains exceptional liquid asset reserves at 46.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Asset Resilience Ratio by Year (2019–2025)
Hubei Biocause Heilen Pharmaceutical Co. Ltd. asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Hubei Biocause Heilen Pharmaceutical Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 46.10% | CN¥1.11 Billion ≈ $162.03 Million |
CN¥2.40 Billion ≈ $351.47 Million |
+2.16pp |
| 2024-12-31 | 43.94% | CN¥1.09 Billion ≈ $160.02 Million |
CN¥2.49 Billion ≈ $364.17 Million |
+38.86pp |
| 2023-12-31 | 5.08% | CN¥129.40 Million ≈ $18.94 Million |
CN¥2.55 Billion ≈ $372.64 Million |
+0.92pp |
| 2022-12-31 | 4.16% | CN¥103.98 Million ≈ $15.22 Million |
CN¥2.50 Billion ≈ $365.50 Million |
-25.72pp |
| 2020-12-31 | 29.88% | CN¥240.00 Million ≈ $35.12 Million |
CN¥803.25 Million ≈ $117.54 Million |
-9.15pp |
| 2019-12-31 | 39.03% | CN¥291.00 Million ≈ $42.58 Million |
CN¥745.56 Million ≈ $109.10 Million |
-- |
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including … Read more